<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659070</url>
  </required_header>
  <id_info>
    <org_study_id>HL-CDP-301</org_study_id>
    <nct_id>NCT04659070</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical&#xD;
      Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Co-administrated&#xD;
      Ezetimibe/Rosuvastatin and Telmisartan in patients with essential hypertension and primary&#xD;
      hypercholesterolemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">May 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean sitting systolic blood pressure (MSSBP)</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>MSSBP change at week 8 compared to baseline, experimental, active comparator1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>LDL-C change at week 8 compare to baseline, experimental, active comparator2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean sitting systolic blood pressure (MSSBP)</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>MSSBP change at week 4 compare to basline, experimental, active comparator1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sitting diastolic blood pressure (MSDBP)</measure>
    <time_frame>baseline, week 4, week 8</time_frame>
    <description>MSDBP change at week 4, 8 compare to baseline, experimental, active comparator1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of patients who have reached their target blood pressure</measure>
    <time_frame>week4, week8</time_frame>
    <description>The rate of patients who have reached their target blood pressure in experimental and active comparator1 at 4 or 8 weeks after administration of clinical trial medications (Average left blood pressure &lt; 140/90mmHg, diabetic or chronic renal disease (only for patients with chronic renal disease with albu manure or proteinuria history) Average left and right blood pressure / 130/80mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of LDL-C change</measure>
    <time_frame>baseline, week4</time_frame>
    <description>Percentage of LDL-C change at week 4 compare to baseline, experimental, active comparator2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C change</measure>
    <time_frame>baseline, week4, week8</time_frame>
    <description>LDL-C change at week 4, 8 compare to baseline, experimental, active comparator2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement rate of LDL-C treatment goals</measure>
    <time_frame>week4, week8</time_frame>
    <description>Achievement rate of LDL-C treatment goals in accordance with NCEP ATP III criteria at 4 and 8 weeks after administration of clinical trial medications, experimental, active comparator2 (Group1 : &lt; 160mg/dL, Group 2: &lt; 130mg/dL, Group 3: &lt; 100mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of lipid indicators change</measure>
    <time_frame>baseline, week4. week8</time_frame>
    <description>Percentage of lipid indicators(TC, HDL-C, TG, LDL-C/HDL-C, TC/HDL-C, non-HDL-C, Apo B) change at week 4, 8 compare to baseline, experimental, active comparator2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid indicators chage</measure>
    <time_frame>basline, week4, week8</time_frame>
    <description>Lipid indicators(TC, HDL-C, TG, LDL-C/HDL-C, TC/HDL-C, non-HDL-C, Apo B) change at week 4, 8 compare to baseline, experimental, active comparator2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Experimental : Ezetimibe / Rosuvastatin + Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator1 : Ezetimibe / Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator2 : Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 80mg PO, Once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental : Ezetimibe / Rosuvastatin + Telmisartan</intervention_name>
    <description>Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks</description>
    <arm_group_label>Experimental : Ezetimibe / Rosuvastatin + Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator1 : Ezetimibe / Rosuvastatin</intervention_name>
    <description>Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks</description>
    <arm_group_label>Active comparator1 : Ezetimibe / Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator2 : Telmisartan</intervention_name>
    <description>Telmisartan 80mg PO, Once daily for 8 weeks</description>
    <arm_group_label>Active comparator2 : Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male and female aged 19 to 79 years of age&#xD;
&#xD;
          2. a patient with congenital hypertension and hypercholesterolemia capable of&#xD;
             administering medicines for Clinical trials planned for this clinical trial, with the&#xD;
             discontinuation of existing therapeutic drugs according to the section.&#xD;
&#xD;
          3. A person who meets the following criteria at the time of screening (visit 1)&#xD;
&#xD;
               -  MSSBP &lt; 180mmHg and MSDBP &lt; 110mmHg&#xD;
&#xD;
               -  LDL-C ≤ 250 mg/dL and TG &lt; 400 mg/dL (based on organ clinical laboratory testing)&#xD;
&#xD;
          4. A person who agrees to contraception through a medically permitted contraception&#xD;
             method during a clinical trial period.&#xD;
&#xD;
               -  Possible pregnant female test subjects: intrauterine device (IUD) or IUS&#xD;
                  (Intrauterine system), intractorine defections, double-blocking method (complex&#xD;
                  use of blocking methods such as male condoms, female condoms, uterine cervical&#xD;
                  caps, contraceptive diaphragm, contraceptive sponges)&#xD;
&#xD;
               -  Male test subjects with potential pregnant spouses (including partners): hormonal&#xD;
                  contraception, intrauterine device (IUD) or IUS (Intrauterine system),&#xD;
                  intraperitoneal failure, double-blocking (male condom, female condom, uterine&#xD;
                  cervical cap, contraceptive diaphragm, and contraceptive blocking)&#xD;
&#xD;
          5. Patients who have agreed in writing to voluntarily participate in this clinical trial&#xD;
&#xD;
        Randomized(Visit 2) criteria&#xD;
&#xD;
          1. If the blood pressure measured at the time of random assignment is as follows:&#xD;
&#xD;
             - 140mmHg ≤ MSSBP &lt; 180mmHg and MSDBP &lt; 110mmHg However, patients with diabetes or&#xD;
             chronic neuropathy: 130mmHg ≤ MSSBP &lt; 180mmHg (In the case of chronic neuropathy&#xD;
             patients, albuinuria or proteinuria history is confirmed until the time of random&#xD;
             assignment.)&#xD;
&#xD;
          2. Therapeutic Lifestyle Change (TLC) after Visit 1 A person whose LDL-C and TG values&#xD;
             correspond to the following group-specific criteria (NCEP ATP III guideline) as the&#xD;
             basis for organ testing at the time of random assignment.&#xD;
&#xD;
               -  Group1 cardiovascular risk factor : 0~1, LDL-C(mg/dL) : 160-250, TG(mg/dL) : &lt;&#xD;
                  400&#xD;
&#xD;
               -  Group2 cardiovascular risk factor : 2 ≤, 10 year risk : &lt; 10% LDL-C(mg/dL) :&#xD;
                  160-250 TG(mg/dL) : &lt; 400 cardiovascular risk factor : 2 ≤, 10% ≤ 10 year risk ≤&#xD;
                  20%, LDL-C(mg/dL) : 130-250 TG(mg/dL) : &lt; 400&#xD;
&#xD;
               -  Group3 coronary artery disease or equivalent (20% &lt; 10 year risk), LDL-C(mg/dL) :&#xD;
                  100-250 TG(mg/dL) : &lt; 400&#xD;
&#xD;
          3. A person who does not have any inappropriate items when re-checking the&#xD;
             selection/excluding criteria at the time of random assignment.&#xD;
&#xD;
        (except items that apply only to screening)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A person suspected of secondary hypertension or secondary hypertension (aortic&#xD;
             stenosis, hyperaldosterone haemorrhage, renal vein stenosis, sacrosanctal&#xD;
             hypertension, chrome-friendly cell species, Cushing syndrome, polycystic neuropathy,&#xD;
             etc.)&#xD;
&#xD;
          2. Secondary dyslipidemia patients (neurological syndrome, dysplasia, closed liver&#xD;
             disease, Cushing syndrome, etc.)&#xD;
&#xD;
          3. Standing low blood pressure patient with symptoms&#xD;
&#xD;
          4. Clinically meaningful ventricular tachycardia, atrial fibrillation, atrial&#xD;
             fibrillation, or other arrhythmia patients that the tester has determined to be&#xD;
             clinically meaningful.&#xD;
&#xD;
          5. Persons with non-post-closing myocardial disease, severe closed coronary artery&#xD;
             disease, aortic stenosis, hemodynamically meaningful aortic valve or mitral valve&#xD;
             stenosis.&#xD;
&#xD;
          6. Patients with severe heart failure (NYHA class III: Symptoms due to mild&#xD;
             exercise/classIV: Symptoms even when stabilized)&#xD;
&#xD;
          7. A person who has one or more of the following forces within the last six months based&#xD;
             on a screening visit (visit 1):&#xD;
&#xD;
               -  Those who have received ischemic heart disease (unstable angina, myocardial&#xD;
                  infarction), peripheral vascular disease, percutaneous coronary artery extension&#xD;
                  or coronary artery bypass treatment, etc.&#xD;
&#xD;
               -  Patients with severe cerebrovascular disorders (brain stroke, cerebral&#xD;
                  infarction, cerebral hemorrhage, routine ischemia, etc.)&#xD;
&#xD;
          8. A person with a history of gastrointestinal diseases (such as Crohn's disease, ulcers,&#xD;
             etc.) and surgery (except simple appendectomy or hernia surgery) that can affect the&#xD;
             absorption, distribution, metabolism, and excretion of drugs.&#xD;
&#xD;
          9. Patients with gastrointestinal diseases such as active gastritis or duodenal ulcer&#xD;
             within one year of screening&#xD;
&#xD;
         10. A person who has a history of muscle toxicity to fibromyalgia, myopathy,&#xD;
             rhabdomyolysis, history of hereditary muscle disease or family history, and past&#xD;
             HMGCoA reducing enzyme inhibitor or fibrate-related drugs.&#xD;
&#xD;
         11. Patients with parathyroidism&#xD;
&#xD;
         12. Patients with shock&#xD;
&#xD;
         13. Patients with biliary obstruction or bile congestion&#xD;
&#xD;
         14. Patients with hereditary vascular edema&#xD;
&#xD;
         15. Patients with a history of vascular edema during ACE inhibitor or Angiotensin II&#xD;
             receptor antagonist treatment.&#xD;
&#xD;
         16. Patients with chronic inflammatory diseases who need continuous anti-inflammatory&#xD;
             treatment&#xD;
&#xD;
         17. Patients with autoimmune diseases, connective tissue diseases&#xD;
&#xD;
         18. Those who have a history of moderate degree or malignant retinopathy (i.e., retinal&#xD;
             bleeding, vision impairment, retinal micro aneurysm) within the previous six months&#xD;
             based on a screening visit (visit 1)&#xD;
&#xD;
         19. On the basis of a screening visit (visit 1) a person with malignancy, including&#xD;
             leukemia and lymphoma, was evaluated as Complete Response (but not recurrent within at&#xD;
             least two years from the screening date, or a malignant tumor that occurred within the&#xD;
             minimum two years of the screening, is the only basal cell carcinoma or squamous skin&#xD;
             cell carcinoma (Square).&#xD;
&#xD;
         20. Patients who have run out of blood or sodium due to high doses of diuretics, dietary&#xD;
             salinity, diarrhea and vomiting.&#xD;
&#xD;
         21. The following institutional clinical laboratory test results (screening criteria) are&#xD;
             available:&#xD;
&#xD;
               -  Patients with active liver disease and severe liver disorder (unknown continuous&#xD;
                  serum AST, elevated or serum ALT, person with AST more than three times the&#xD;
                  normal upper limit)&#xD;
&#xD;
               -  a person whose CPK (creatine phosphokinase) level is more than twice the normal&#xD;
                  upper limit.&#xD;
&#xD;
               -  Creatine clearance (CLcr) &lt; 30mL/min or eGFR &lt; 30ml/min/1.73m2.&#xD;
&#xD;
               -  a person with low potassium haemorrhage (less than 3.5 mmol/L) or high potassium&#xD;
                  haemorrhage (greater than 5.5 mmol/L)&#xD;
&#xD;
               -  Unregulated diabetics (HbA1c &gt; 9.0%)&#xD;
&#xD;
               -  Unregulated thyroid dysfunction with a TSH level of 1.5 times or more than the&#xD;
                  normal upper limit&#xD;
&#xD;
         22. In case of the following allergic and hypersensitive history:&#xD;
&#xD;
               -  someone with drug allergy-response anaphylaxis or hepatotoxicity.&#xD;
&#xD;
               -  Angiotensin II receptor blocker family drug or HMG-CoA reducing enzyme inhibitor&#xD;
&#xD;
               -  A person who has overreacted to a clinical trial drug or is hypersensitive to the&#xD;
                  composition of a clinical trial drug&#xD;
&#xD;
               -  A person who has genetic problems such as galactose intolerance, Lap lactase&#xD;
                  deficiencies, or glucose-galactose malabsorbtion.&#xD;
&#xD;
         23. A person who is administering a prohibited drug in this clinical trial or is expected&#xD;
             to be administered during the clinical trial period.&#xD;
&#xD;
         24. Those who showed a difference of SBP ≥ 20 mmHg and DBP ≥10 mmHg in three consecutive&#xD;
             measurements at least two minutes apart on each arm during a screening visit (visit 1)&#xD;
&#xD;
         25. Patients who cannot stop anti-hypertensive drugs or lipid-control drugs that were&#xD;
             being administered during a screening visit (visit 1) during the clinical trial&#xD;
             period.&#xD;
&#xD;
         26. Those who have or are suspected of drug or alcohol abuse within one year prior to the&#xD;
             screening visit (visit 1)&#xD;
&#xD;
         27. Pregnant or breastfeeding women&#xD;
&#xD;
         28. A person who has received another clinical trial medication within three months of the&#xD;
             first administration of the clinical trial medication in this clinical trial (if&#xD;
             he/she has not administered the clinical trial medication or has participated in&#xD;
             non-release observation research, he/she may register).&#xD;
&#xD;
         29. A person who is deemed unfit by the tester (the physician in charge) to participate in&#xD;
             this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kee Sik Kim, CI</last_name>
    <phone>053-650-4455</phone>
    <email>kks7379@cu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyoung Hee Baek, PM</last_name>
    <phone>82-2-3489-6160</phone>
    <email>khbaek@hanlim.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Daegu Catholic Univ Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Sik Kim, PI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

